Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

Korea Bizwire reports South Korea's move to make PrEP available. Its Ministry of Food and Drug Safety approved the sale of Truvada for prevention. The article also covers continuing questions about the cost of PrEP.

February 20, 2018
Korea Bizwire

A new modeling study recently published in the Journal of Acquired Immune Deficiency Syndromes estimated that more than 30% of HIV infections in the United States could be prevented if at least 25% of men who have sex with men at risk for HIV receive pre-exposure prophylaxis, or PrEP. This estimate exceeds a goal set by the United States’ National HIV/AIDS Strategy to reduce 25% of new infections by 2020.

December 21, 2017

Pharmaceutical giant Gilead, which manufactures the HIV anti-retroviral drug Truvada, has withdrawn its appeal against the High Court’s refusal to grant an injunction against generic manufacturers.

December 20, 2017
The Irish Times
Subscribe to RSS - PrEP